Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CCKBR | P32239 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21972248 | 0.85 | PDGFRB (0.69) | PDGFRBHTTALDH1A1TSHRKDM4E | |
| SCHEMBL21971388 | 0.85 | PDGFRB (0.54) | PDGFRBHTTALDH1A1KDM4ELMNA | |
| SCHEMBL21970636 | 0.85 | PDGFRB (0.50) | PDGFRBHTTALDH1A1TSHRCCKBR | |
| SCHEMBL21970995 | 0.79 | PDGFRB (0.58) | PDGFRBHTTALDH1A1TSHRKDM4E | |
| SCHEMBL21972252 | 0.76 | PDGFRB (0.42) | PDGFRBALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL21972254 | 0.70 | PDGFRB (0.42) | PDGFRBHTT | |
| SCHEMBL21971400 | 0.70 | PDGFRB (0.58) | PDGFRBHTTALDH1A1TSHRCCKBR | |
| SCHEMBL21970985 | 0.70 | PDGFRB (0.49) | PDGFRBALDH1A1GAA | |
| SCHEMBL21970984 | 0.68 | PDGFRB (0.56) | PDGFRBHTTALDH1A1TSHRKDM4E | |
| SCHEMBL20739540 | 0.67 | PDGFRB (0.69) | PDGFRBHTTALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046655-B2 | Compound and method for producing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-20200140394-A1 | NOVEL COMPOUND AND METHOD FOR PRODUCING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140394-A1 | NOVEL COMPOUND AND METHOD FOR PRODUCING SAME | CBR3, NR2E3, NR5A2 | PDGFRB 2517/4885HTT 4598/4885ALDH1A1 1147/4885 |
| US-11046655-B2 | Compound and method for producing same | CBR3, NR5A1, NR2E3 | PDGFRB 2499/4885HTT 4012/4885ALDH1A1 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.